aTyr Pharma (NASDAQ:ATYR) Posts Earnings Results, Misses Estimates By $3.43 EPS

aTyr Pharma (NASDAQ:ATYR) posted its quarterly earnings results on Thursday. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43), FiscalAI reports.

aTyr Pharma Stock Performance

NASDAQ ATYR traded down $0.15 on Thursday, hitting $6.03. The stock had a trading volume of 58,833 shares, compared to its average volume of 100,043. aTyr Pharma has a 52-week low of $4.07 and a 52-week high of $44.40. The firm has a 50-day moving average of $11.99 and a 200-day moving average of $23.70.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ATYR. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Wall Street Zen upgraded aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.